Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options.

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75

Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44

Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74

Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90

The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev (1989) 13.15

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst (2002) 12.07

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28

Mechanisms of bone metastasis. N Engl J Med (2004) 10.40

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer (2007) 3.15

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet (2001) 2.85

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int (2010) 2.15

Commentary on "Abiraterone in metastatic prostate cancer without previous chemotherapy." Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators, Genitourinary Medical Oncology Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA. N Engl J Med 2013;368(2):138-48 [Epub 2012 Dec 10]; N Engl J Med 2013;368(6):584. Urol Oncol (2013) 2.08

Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res (1980) 1.97

Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2013) 1.95

Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer (2010) 1.33

Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol (2011) 1.31

Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev (1999) 1.30

Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer (2012) 1.16

NCCN welcomes 2 new member institutions. J Natl Compr Canc Netw (2013) 0.84

The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma. P T (2013) 1.68

Renewing the assault on mRNA. Biotechnol Healthc (2004) 0.81

The cancer genome atlas: new weapon in old war? Biotechnol Healthc (2006) 0.77

William B. White Explains the Changes In the Way We Look at Blood Pressure: Which Numbers Matter Most-and Why Can They Be Deceptive? P T (2016) 0.75

To Heal the Body, Get Into the Patient's Head: Motivational Interviewing: To improve adherence. Biotechnol Healthc (2012) 0.75

Doing more with less?: past and present challenges for the FDA. P T (2011) 0.75

Carlos Fernández-del Castillo Confronts The Challenge of Pancreatic Cancer: Although Progress Has Been Slow, a Renowned Expert On the Disease Sees Reasons for Hope. P T (2014) 0.75

Kenneth tanabe works to solve the mysteries of liver cancer: while progress has been relatively slow, this noted expert sees reasons for hope. P T (2015) 0.75

Connecting Patients With Specialty Products: Part 2: The future of specialty drug distribution. Biotechnol Healthc (2012) 0.75

Does race have a place in biotechnological research? Biotechnol Healthc (2005) 0.75

First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2- Breast Cancer. P T (2015) 0.75

P&T committees in position to reduce medication errors. Manag Care (2004) 0.75

When timing is of the essence. Biotechnol Healthc (2005) 0.75

Part 1: Distribution models for biologics and other specialty pharmaceutical products: In this first of a two-part series, we examine the distribution landscape for specialty pharmaceuticals. A manufacturer's strategy for the flow of product to patient has important implications for payers and for the success of a new biologic therapy. Biotechnol Healthc (2012) 0.75

The weight debate, continued. Manag Care (2004) 0.75

Could QALYs help in assessing high-priced cancer treatments? Manag Care (2013) 0.75

Chimeric Antigen Receptor T-Cell Therapy: The Next Big Thing Faces Challenges. Manag Care (2017) 0.75

Prediabetes: Pre- Does Not Mean Preordained. Manag Care (2016) 0.75

Flu's other cost. Manag Care (2005) 0.75

Hospital at home saves 19% in real-world study. Manag Care (2012) 0.75

Managed care (and everyone else) unprepared for the next killer flu. Manag Care (2005) 0.75

Shaking the tree of life. Biotechnol Healthc (2004) 0.75

The future of gene therapy. Biotechnol Healthc (2005) 0.75

Choosing the right oral antiplatelet medication. Manag Care (2013) 0.75

Health plans respond as microbes develop resistance techniques. Manag Care (2004) 0.75

Statin therapy: more than meets the eye? Manag Care (2004) 0.75

A Method to the mAbNESS? Biotechnol Healthc (2004) 0.75